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- Around 90% of thyroid cancers are papillary thyroid carcinomas (PTC)1
- PTC has a recurrence rate of around 20%1
- Mortality rate for PTC is low at around 5%2
- Extrathyroidal extension, multifocality, positive margins, and lymph node 
metastases are predictors of more aggressive PTC4
- BRAFV600E occurs in 60% of PTCs3
- There is controversy whether BRAFV600E is an independent predictor 
of aggressiveness5
METHODS
- Specimens and clinical data were obtained from the ICARE2 
biospecimen and bioinformatics registry at UNMC
- Adult patients with PTC treated with surgery and greater than 6 months 
of post-operative follow-up were included
- Tissue microarrays (TMA) were made from well-differentiated tumors
- Immunohistochemistry for BRAFV600E was performed on all TMAs, 
positive cytoplasmic staining was inferred to represent the BRAF 
mutation
- BRAFV600E expression was calculated by an H-score: staining 
intensity (0-3) multiplied by quantity of staining (% positive)
- Statistical analysis was performed using Pearson Chi squared, Fisher's 
exact, and Wilcoxon rank-sum tests to determine factors associated 
with BRAFV600E
- Multivariable logistic regression used to determine independent factors 
associated with recurrence
- A Kaplan-Meier analysis was performed to assess for recurrence over 
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INTRODUCTION
- BRAFV600E is not an independent predictor of recurrence and outcomes 
in PTC
Features associated with recurrence
Variable Odds Ratio p value
BRAFV600E mutation 1.5 0.704
Age 0.96 0.159
Lymph node ratio 9.9 0.071
Extrathyroidal extension 43.5 0.001
Positive margin 2.8 0.33
Histology 0.99 0.982
Gender 4.5 0.173
Response to therapy 0.93
Excellent, n (%) 112 (70.4) 45 (70.3) 67 (70.5)
Indeterminate, n (%) 31 (19.5) 12 (18.8) 19 (20)
Biochemically incomplete, n (%) 14 (8.8) 6 (9.4) 8 (8.4)
Structurally incomplete, n (%) 2 (1.3) 1 (1.6) 1 (1.1)
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Table 2. Cancer Staging for Patients with WDTC by BRAF Status
All BRAF WT BRAFV600E P-Value
Patients 160 65 95
T stage 0.58
T1a, n (%) 34 (21.4) 14 (21.5) 20 (21.3)
T1b, n (%) 44 (27.7) 18 (27.7) 26 (27.7)
T2, n (%) 35 (22) 18 (27.7 17 (18.1)
T3, n (%) 44 (27.7) 14 (21.5) 30 (31.9)
T4a 2 (1.3) 1 (1.5) 1 (1.1)
N stage 0.015
N0, n (%) 101 (63.5) 49 (75.4) 52 (55.3)
N1a, n (%) 35 (22) 9 (13.85) 26 (27.7)
N1b, n (%) 23 (14.5) 7 (10.8) 16 (17)
M stage 0.81
M0, n (%) 156 (99..4) 62 (98.1) 92 (97.9)
M1, n (%) 3 (1.91) 1 (1.59) 2 (2.13)
AJCC 8 stage 0.0042
I, n (%) 111 (69.8) 63 (96.9) 77 (81.9)
II, n (%) 15 (9.4) 2 (3.1) 16 (17)
III, n (%) 1 (0.63) 0 (0) 1 (1.1)
All BRAF WT BRAFV600E P-Value
ATA risk category 0.018
Low, n (%) 77 (48.7) 40 (61.5) 37 (39.8)
Intermediate, n (%) 66 (41.8) 19 (29.2) 47 (50.5)
High, n (%) 15 (9.5) 6 (9.2) 9 (9.7)
Radioactive iodine treatment, n (%) 82 (51.3) 29 (44.6) 53 (55.8) 0.17
Recurrence, n (%) 22 (13.8) 6 (9.2) 16 (16.9) 0.17
Recurrence time, years, mean, (SD) 1.9 (2.0) 0.84 (0.94) 2.3 (2.1) 0.0487
Mortality, n (%) 6 (3.8) 2 (3.1) 4 (4.3) 0.7
Table 1: Clinical/Demographic Variables of Patients with PTC by BRAF Status
All BRAF WT BRAFV600E P-Value
Patients 160 65 95
Age, years, mean (SD) 45.5 (14.2) 42.3 (14.3) 47.6 (13.7) 0.0259
Age over 55, n (%) 43 (26.9) 11 (16.9) 32 (33.7) 0.019
Gender, female, n (%) 125 (78.12) 56 (86.2) 69 (72.3) 0.042
Body mass index, kg/m^2, mean (SD) 31.41 (7.0) 30.4 (6.8) 32.1 (7.1) 0.108
Tumor size, cm, mean (SD) 2.0 (1.4) 2.2 (1.6) 1.9 (1.3) 0.1833
Histology 0.0002
FV Papillary thyroid carcinoma, n (%) 35 (22) 24 (36.9) 11 (11.7)
Papillary thyroid carcinoma, n (%) 124 (78) 41 (63.1) 83 (88.3)
Lymphocytic thyroiditis, n (%) 56 (35) 22 (33.9) 34 (35.8) 0.8
Extrathyroidal Extension, n (%) 34 (28.1) 9 (18.4) 25 (34.7) 0.049
Multifocality, n (%) 60 (37.5) 20 (30.8) 40 (42.1) 0.15
Positive margins, n (%) 22 (14) 4 (6.4) 18 (19.2) 0.033
Vascular Invasion 16 (11) 10 (16.4) 6 (7.1) 0.079
Lymphatic Invasion 17 (11.4) 9 (14.3) 8 (9.3) 0.32
Lymph node size, cm, mean (SD) 1.6 (1.3) 1.8 (1.4) 1.5 (1.3) 0.6531
Lymph node ratio, n, mean (SD) 0.19 (0.32) 0.13 (0.3) 0.23 (0.33) 0.0106
Extranodal extension, n (%) 21 (18.8) 9 (22.5) 12 (16.7) 0.45
Follow-up time, years, mean (SD) 6.0 (2.9) 6.1 (3.2) 6.0 (2.6) 0.91
- BRAFV600E is not an independent predictor of recurrence in this cohort
- BRAFV600E is associated with extrathyroidal extension, male gender, age, positive 
surgical margins, lymph node ratio, histology, ATA risk category, N stage, and AJCC 
8 stage in univariate analysis
- Response to therapy is no different in BRAFV600E and WT groups
- Multivariable analysis showed only extrathyroidal extension as an independent 
predictor of recurrence
- Current treatment recommendations based on risk of recurrence appear to be 
appropriate and should not incorporate BRAFV600E as an independent variable
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Figure 1: H&E (1,3) and IHC (2,4) stained slides of tumors that are BRAF negative (1,2) and BRAF positive (3,4)
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Kaplan-Meier WDTC Recurrence Estimates by BRAF Status for Patients Over Age 55 at Diagnosis
